FDA Grants Approval for Teva's Tolvaptan ANDA216933
Teva Pharmaceuticals has received an approval for their Abbreviated New Drug Application (ANDA216933) for Tolvaptan.
Published: July 25, 2026
Updated: July 25, 2026
Author: Humanexa Intelligence
Therapeutic area: Nephrology / Vasopressin Antagonist
Company: Teva
Asset: Tolvaptan
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Teva's generic Tolvaptan introduces competitive pressure on existing branded products, which may lead to pricing changes and market share shifts. Portfolio teams must evaluate the implications for their own Tolvaptan offerings to sustain competitive positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of Teva's Tolvaptan product.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.